Compare Crispr Therapeutics AG (CRSP) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Sezzle Inc — how do they compare? Crispr Therapeutics AG trades at $50.51 (market cap $4.97B), while Sezzle Inc trades at $192.08 (market cap $6.15B). The key difference: Sezzle Inc is the larger of the two by market cap, and Sezzle Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | SEZL | |
|---|---|---|
Market Cap | $4.97B | $6.15B |
Sector | Health | Technology |
52-Week High | $76.78 | $183.24 |
52-Week Low | $44.34 | $50.97 |
Enterprise Value | $3.32B | $6.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
SEZL trades at $160.25, down 10.66% over the last session, but maintains a bullish technical outlook with support at $156 and resistance at $165. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.43, and raised full-year guidance. Revenue growth accelerated to 29% year-over-year, with net income margin expanding to 30.83%.
Outlook remains positive given consistent earnings beats and product expansion, though high valuation multiples (P/E 43.68) and a recent securities law investigation pose risks. Analyst consensus is split evenly between Buy and Hold, with a $162 price target suggesting modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
